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Abstract
Background: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate
whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer.
Methods: A tissue microarray, made with specimens from consecutive 261 patients who received oxaliplatin based
adjuvant chemotherapy, was stained with anti-SLFN11 antibody. The staining was dichotomized as high or low
expression. SLFN11 expression was correlated to clinicopathological factors, KRAS exon 2 mutation and survival.
Results: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 %
of patients. SLFN11 was expressed more common in well/moderate differentiation tumors(comparing to poor
differentiation ones, 21 % v 4.9 %, P = 0.003) and stage II tumors(comparing to stage III tumors, 26.1 % v 11.4 %,p = 0.006).
23 out of 153 patients with KRAS exon 2 wild-type CRC had SLFN11 high expression, no death events was recorded in
the 23 patients until last follow up. These patients had significantly better overall survival (OS) than those with SLFN11 low
expression tumors (100 % vs 78.2 %, log rank P = 0.048). However, among patients with KRAS exon 2 mutant tumors, OS
did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).
Conclusions: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type
who have received oxaliplatin based adjuvant chemotherapy.
Background
Genes of the Schlafen (SLFN) family are differentially
regulated during thymocyte maturation. SLFN 1 in the T
lineage profoundly alters cell growth and development.
SLFNs have been linked to growth suppression, differen-
tiation, and apoptosis [1]. SLFN11 belongs to group 3-
SLFN family, and harbors a motif found in superfamily I
DNA/RNA helicases [1]. SLFN11 expression was identi-
fied as the main correlate of sensitivity to irinotecan, a
camptothecin analog that inhibits topoisomerase I
(TOP1) [2]. SLFN11 expression is also very significantly
correlated with response to Top2 inhibitors, alkylating
agents, and DNA synthesis inhibitors, all of which are
characterized as DNA-damaging agents (DDAs) [3].
DDAs are a mainstay of treatment for most human tu-
mors. SLFN11 expression is causally associated with ac-
tivity of DDAs in cancer cells [2, 3].
SLFN11 expression reportedly predicts independently
overall survival (OS) in ovarian cancer patients treated
with cisplatin-based regimens [3]. Oxaliplatin and cis-
platin have a similar anti-tumor mechanism, which causes
DNA damage. A range of SLFN11 expression in colorectal
cancer (CRC) has been observed [3]. In this study, we in-
vestigated SLFN11 expression in stage II–III CRCs treated
with oxaliplatin-based adjuvant chemotherapy (FOLFOX),
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Two hundred sixty one consecutive patients with high
risk stage II or III colorectal adenocarcinoma treated be-
tween May 2007 and May 2012 were included in the
study. All patients underwent quality assessed curative
surgery and had received at least 3 month oxaliplatin
based adjuvant chemotherapy in the Gastrointestinal
Hospital of Sun Yatsen University. High risk factors for
stage II disease included T4, vascular tumor invasion,
poor differentiation, lymph node examination less than
12, and preoperative obstruction. This study was ap-
proved by the Medical Ethics Committee of Gastrointes-
tinal Hospital of Sun Yatsen University. All patients gave
informed consent for the use of tumor samples. Staging
procedures, including colonoscopy, contrast enhanced
CT scans of thorax, abdomen and pelvis and pelvic
MRIs(rectal cancer), were performed in all cases to con-
firm locally advanced tumor stage and to exclude pa-
tients with evidence of distant metastatic disease at the
initial diagnosis. Patients with family hereditary disease
and multi-primary lesions were excluded.
Treatment procedures
Pathological staging were determined according to Ameri-
can Joint Committee on Cancer (AJCC) guidelines. Adju-
vant chemotherapy was started within 8 weeks after
radical operation. Chemotherapy regimens contained
mFOLFOX6(oxaliplatin 85 mg/m2 iv drip d1 + leucovorin
400 mg/m2 iv drip d1 + 5-Fluorouracil 400 mg/m2 iv d1 +
5-Fluorouracil 2400 mg/m2 CIV 46 h) or a few CAPOX(-
oxaliplatin 130 mg/m2 iv drip d1 + capecitabine 1000 mg/
m2 bid d1-d14). Some rectal cancer patients received a
total irradiation dose of 46 Gy in 23 fractions of 2 Gy
with concomitant application of 5-fluorouracil (5-FU)
prior to operation.
Preparation of the tissue microarray
Paraffin blocks containing areas of invasive carcinoma
were identified on corresponding H and E-stained sec-
tions. Areas of interest that represented the invasive
front of the tumor, rich in non-necrotic tumoral glands,
were identified and marked on the source block. The
source block was then cored and a 1-mm core trans-
ferred to the recipient block using the Beecher Tissue
Microarray (Beecher Instruments, Silver Spring, MD,
USA). Two cores were arrayed per specimen.
Immunohistochemistry staining and score
Tissue microarray slides were fixed in 10 % buffered for-
malin and embedded in paraffin. Sections were cut at
3 μm thickness, and mounted on coated glass slides. Slides
were deparaffinized and heated. Sections were incubated
with the primary anti-human SLFN11 antibody (1:50,
Abcam). Negative controls underwent the same proto-
col with isoform antibody in a humidified chamber, and
were refrigerated at 4 °C overnight. Incubated with
polyperoxidase-anti-mouse/rabbit IgG (Zymed) for
15 min, 3,3′-diaminobenzidine was used as the chromo-
gen. Immunostaining was evaluated by two independent
pathologists blinded to the study. Agreement was achieved
by discussion if there were discordance. Expression was
analyzed by an individual labeling score considering per-
cent of positive cells and staining intensity. Intensity was
scored as 0, none; 1, weak; 2: moderate; 3, strong. The
proportion of positive tumor cells was assigned to 0
(<25 % positive), 1 (25–50 % positive), 2 (50–75 % posi-
tive), 3 (75–100 % positive). The final score was calculated
by intensity plus proportion (0–6).
DNA preparation and KRAS mutational analysis
Formalin-fixed, paraffin-embedded tumor tissues were
collected from Pathological tissue bank of Gastrointestinal
Hospital of Sun Yat-sen University. All the tissue samples
were confirmed independently by two gastrointestinal pa-
thologists. Genomic DNA was extracted with the DNA
FFPE tissue extracted Kit (BIOMIGA), according to the
manufacturer’s recommendations.
The primers for the amplification and Sanger dideoxy
chain termination sequencing of KRAS gene were for-
ward: 5′- GTCCTG CACCAGTAATATGC-3′ and re-
verse: 5′-ATGTTCTAATATAGTCACATTTTC-3′ for
codon 12 and 13. PCR was performed using 100 ng gen-
omic DNA as template. Each mixture contained 10 pmol
of each primer. The reactions were performed in a total
volume of 31.45 μl. The amplification reaction were as fol-
lows: an initial denaturing cycle of 95 °C for 5 min; 45 cy-
cles of 94 °C for 25 s, 58 °C for 25 s, 72 °C for 25 s; and a
final extension cycle at 72 °C for 10 min. The PCR prod-
ucts were then purified and subjected to direct sequencing
using the automatic sequencer (ABI-3730 Genetic Ana-
lysis, Applied Biosystems).
Clinical evaluation and follow-up
All patients were reevaluated at 3-month intervals for
2 years and every 6 months thereafter. Evaluations con-
sisted of pertinent medical history, physical examination,
blood cell counts, and blood chemistry including carci-
noembryonic antigen (CEA) levels at every follow-up
visit. Colonoscopies (in patients treated with anterior re-
sections) were performed at 6-month intervals in the
first 2 years, and annually thereafter. Follow-up chest,
abdomen and pelvis CT studies were scheduled every
6 months for the first 3 years, and annually thereafter.
Histological confirmation of local recurrence and distant
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relapse (defined as tumor manifestation outside the pelvis)
was encouraged. Alternate acceptable criteria included se-
quential enlargement of a mass in radiologic studies with
simultaneous increase of serum CEA levels. Overall sur-
vival was defined as the time from surgery to detection of
death. Median follow-up time was 49 months (range: 19–
78 months). Follow up rate for this cohort was 95.6 %, 9
patients was lost during surveillance.
Statistical analysis
Statistical analysis used SPSS 17.0. Frequency tables were
analyzed using the χ2 test, with the likelihood ratio (LR) or
Fisher’s exact test for categorical variables. Correlation of
SLFN11 with clinical outcome variables was computed by
Spearman rank correlation. ROC curve was used to set
the cut-off point. Time to event data were visualized using
Kaplan–Meier analysis with log rank test. Both univariate
and multivariate survival analyses were carried out using
Cox proportional hazard regression models. We estimated
hazard ratios (HRs) with the fitted model coefficients
and computed 95 % confidence intervals (CIs) and p
values with Wald tests. P ≤ 0.05 was considered signifi-
cant for all tests.
Results
SLFN11 expression status in CRC patients
The intensity and proportion of SLFN11 staining was
shown in Fig. 1a and b respectively. SLFN11 expression
was successfully obtained in 90.8 % (237/261) of CRC
specimens tested. 237 patients were included in analysis
for the following results. In a ROC curve for OS prognos-
tic sensitivity and specificity of SLFN11 showed, the area
under the curve was 0.526 (Fig. 1c) and the optimal cut-
off was 4.5. We chose the cut-off point to dichotomize
SLFN11 levels into high (>4.5) (SLFN11high) and low
(<4.5) (SLFN11low). By this standard, 16.9 % (40/236) of
patients tested had SLFN11high tumors.
Association of SLFN 11 expression with
clinicopathological features
Table 1 shows patients’ clinicopathological characteris-
tics. We then correlated SLFN11 expression with
Fig. 1 The typical staining of intensity: 0, none; 1, weak; 2: moderate; 3, strong (a). The typical staining of proportion: 0 (< 25 % positive), 1 (25–50 %
positive), 2 (50–75 % positive), 3 (75–100 % positive) (b). ROC curve for SLFN11 expression score, the AUC = 0.526 (c)
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clinicopathological features of CRC, including primary
tumor location, tumor differentiation, preoperative Can-
cinoembryonic Antigen(CEA) level, TNM staging, KRAS
exon 2 status, age and sex. SLFN11 expression was
expressed more in well/moderate differentiated tumors(-
compared to poor differentiated tumors, 21.0 % vs 4.9 %,
P = 0.003) and stage II tumors(compared to stage III tu-
mors, 26.1 % vs 11.4 %, P = 0.005).
SLFN11 and survival
The 3y-DFS and 5y-OS for the cohort was 78.9 % and
79.4 % respectively. Stage III patients have worse prog-
nosis than stage II patients in terms of 3y-DFS(68.5 % v
88.2 %, HR 2.750, 95 % CI 1.424–5.311, P = 0.003) and
5y-OS(73.4 % v 89.5 %, HR 2.501, 95 % CI 1.199–5.217,
P = 0.015), which was concordant with published data.
Patients with SLFN11 high expression tumors tend to
have better overall survival than those with SLFN11 low
expression tumors. (86.8 % vs 80.6 %, HR 0.649, 95 % CI
0.229–1.837, Log rank P = 0.411, Fig. 2).
SLFN11, KRAS and survival
Among 237 patients, 216 had available KRAS and sur-
vival data. The DFS and OS according to KRAS exon 2
status or SLFN11 expression status was shown in Table 2.
In the cohort, 63 out of 216 had KRAS exon 2 mutated
(KRAS-mt) CRC. OS for patients with KRAS exon 2 wild
type (KRAS-wt) and KRAS-mt tumors was almost identi-
cal (80.6 % vs 82.8 %, Log Rank P = 0.823). If OS for the
KRAS-wt group were analyzed separately from the
KRAS-mt group in Kaplan–Meier analysis, overall sur-
vival curves of patients with SLFN11high tumors and
those with SLFN11low tumors separated significantly
(100 % vs 78.2 %, P = 0.048, Fig. 3a); the SLFN11high
group had longer survival. In contrast, in the KRAS-mt
group, patients with SLFN11high or SLFN11low tumors
did not significantly differ in OS (81.9 % vs 80.2 %, P =
0.709, Fig. 3b). Among 23 KRAS-wt and SLFN11 high
expression patients, Only 2 recurrences were detected
and no death was recorded. As SLFN11high expression
was more common in stage II. We did additional sub-
group analysis according to the stage, in patients KRAS-
wt tumors and found patients with SLFN11high tumors
had a trend of better survival than that with SLFN11low
tumors in both stage II (Fig. 4a) and stage III CRC, more
prominent in stage III (100 % vs 72 %, Log-rank P =
0.092, Fig. 4b). NRAS and BRAF mutation was tested in
KRAS exon 2 wild type patients, 10 and 3 patients were
identified as mutation respectively. The results remained
the same after exclude the 13 patients (data not shown).
Discussion
The Schlafen (SLFN) family of proteins (from the Ger-
man word Schlieffen, “sleeping”) includes several mouse
and human members. Emerging evidence associates
Schlafen proteins with control of cell proliferation, in-
duction of immune responses, and regulation of viral
replication. The family shows great diversity, with 10
murine and 5 human isoforms. This multigene family is
reportedly comprised of three groups, which can be clas-
sified by the size of the encoded proteins [1, 4–6].
All SLFN proteins share a highly conserved N-terminal
domain (AAA) that is involved in ATP/GTP binding [7];
however, only group III SLFNs, including SLFN11, harbor
a motif found in superfamily I DNA/RNA helicases. Stable
knockdown of SLFNs in malignant melanoma cells re-
sulted in gain of stem-like properties, such as increased
anchorage-independent growth, as evidenced by enhanced
colony formation in soft agar assays [8]. In the intes-
tinal mucosa, SLFN 3 helps regulate intestinal epithelial
Table 1 Patient clinicopathological characteristics and SLFN11
expression
SLFN11Low SLFN11High P
Age (y) 55.72 ± 12.48 57.68 ± 9.98 0.351
Sex Male 112 21
Female 85 19 0.727
Site Left 43 4
Right 154 36 0.126
Grade Well/Moderate 139 37
Poor/Undifferentiated 58 3 0.003
TNM stage II 65 23
III 132 17 0.006
KRASa Wild type 136 23
Mutation 54 12 0.545
CEA(ng/ml)a 8.6 ± 17.57 10.34 ± 13.63 0.601
a KRAS data was available in 225 patients, CEA data was available in 200 patients
Fig. 2 Log rank survival analysis showed no difference between
patients with high and low SLFN11 expressing tumors in the cohort
as a whole (Log rank P = 0.411)
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differentiation [9, 10] and affects intestinal develop-
ment and maturation [11]. SLFN 3 exhibits antiprolifer-
ative properties, as evidenced by the fact that ectopic
expression of SLFN 3 in human colon cancer cells sig-
nificantly decreases proliferation [12]. In the current
study, we found significant correlation between SLFN11
high expression and tumor differentiation. Poor or dif-
ferentiated tumors tended not to express SLFN11,
which accords with the ability of group III SLFNs to
lead cells to differentiate and mature. SLFN11 could be
a differentiation marker for CRC cells, and might be
useful in stem cell separation.
DNA-damaging agents (DDAs) are a mainstay of treat-
ment for most human tumors [13]. Both oxaliplatin and
5-FU are DDAs. The FOLFOX regimen is based on oxa-
liplatin and 5-FU, and is widely used in treating CRCs in
both adjuvant and palliative settings. Zoppoli et al.
showed SLFN11 expression had an extremely significant
Table 2 Univariate survival analysis based on KRAS status or SLFN11 expression status
DFS OS
No. 3y-DFS(%) HR(95 %CI) P 5y-OS HR(95 %CI) P
Patients with KRAS wt
SLFN11high 23 91.3 0.347(0.083–1.449) 0.147 100.0 0.05
SLFN11low 130 75.8 1 83.3
Patients with KRAS mt
SLFN11high 12 72.9 1.424(0.391–5.188) 0.592 80.2 1.348(0.279–6.508) 0.71
SLFN11low 51 83.9 1 81.9 1
Patients with SLFN11high
KRAS wt 23 91.3 1 0.207 100.0 0.06
KRAS mt 12 72.9 3.167(0.528–18.979) 80.2
Patients with SLFN11low
KRAS wt 130 75.8 1 0.511 80.5 0.503
KRAS mt 51 83.9 0.787(0.386–1.607) 81.9 0.749(0.321–1.746)
Fig. 3 Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low
SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had
almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)
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positive correlation with response to Top1 inhibitors
(topotecan and irinotecan), Top2 inhibitors (doxorubi-
cin, mitoxantrone, etoposide), DNA alkylating agents
(chlorambucil, melphalan, cisplatin), and DNA synthesis
inhibitors (gemcitabine and fludarabine) [3]. They also
found that SLFN11 is causative in determining cell death
and cell cycle arrest in response to DDAs in cancer cells
that originate from different tissue types [3]. SLFN11 is a
determinant of the cellular responses to DNA damage [3].
High SLFN11 expression independently predicted OS in a
group of ovarian cancer patients treated with cisplatin-
containing regimens [3]. Colon adenocarcinoma samples
can have a range of SLFN11 expression to >600 % of the
smallest level. SLFN11 expression could be a biomarker
for response to adjuvant FOLFOX treatment of CRC. The
current study is the first to report that FOLFOX sensitivity
in SLFN11high tumors was better than that in SLFN11low
tumors, but the effect was confined to KRAS exon 2 wild-
type patients. Because all patients in this cohort received
oxalipatin-based treatment, SLFN11 could be consid-
ered as both a prognostic and predictive factor in KRAS
wt subgroup.
To the best of our knowledge, this is the first study that
directly correlates SLFN11 expression in IHC staining
with survival and other clinicopathological factors in CRC.
SLFN11 tends to not express in poor differentiation can-
cers and our results imply that it can sensitize CRC cells
to respond to oxaliplatin-based treatment. These findings
provide valuable new information that advances our un-
derstanding of oxaliplatin based therapy in the adjuvant
setting for patients with CRC. The precise mechanism by
which SLFN11 sensitizes KRAS exon 2 CRC cells remains
to be established. Stratifying patients with CRC by
SLFN11 high or low expression may improve manage-
ment and treatment of this disease and improve overall
survival. Moreover, these findings raise the possibility of a
strategy to enhance antineoplastic effects of some agents
by developing drugs that promote SLFN11 expression.
The limitations of the study are as follows. First, this
was a single center retrospective study. Second, the popu-
lation of SLFN11 high expression patients was small.
Therefore, prospective studies are warranted to verify the
role of SLFN11 in all RAS wild-type patients.
Conclusions
SLFN11 expression predicts good better survival in colo-
rectal cancer patients with KRAS exon 2 wild type who
have received oxaliplatin based adjuvant chemotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YD conceived of the study and sponsored the study, performed data
analysis, and participated in manuscript draft. YC carried out clinical
information collection, patient follow up, participated in manuscript draft. YH
carried out the pathological reports and participated in IHC staining. YZ
participated in data analysis, tissue microarray and IHC staining. YB
participated in making TMA, IHC staining and pathological reports. YL
participated in the clinical information collection and patients’ surveillance.
XP participates in making tissue array and IHC staining. JW participated in
designing and gave valuable comments on the study. All authors read and
approved the final manuscript.
Fig. 4 SLFN11 high expression patients had a trend of better survival than SLFN11 low expression patients both in stage II(a) and stage
III(b) patients
Deng et al. BMC Cancer  (2015) 15:833 Page 6 of 7
Acknowledgements
We thank Yaxi Zhu who provided advices in setting the experiment
condition for immunohistochemical staining. The study was supported by
China National Natural Science Foundation (No. 81472249) for data
collection and analysis.
Author details
1Department of Medical Oncology, Gastrointestinal Hospital, Sun Yat-sen
Universtiy, Guangzhou 510655, China. 2Department of Pathology,
Gastrointestinal Hospital, Sun Yat-sen Universtiy, Guangzhou 510655, China.
3Department of Research Institute, Gastrointestinal Hospital, Sun Yat-sen
Universtiy, Guangzhou 510655, China. 4Department of Colorectal Surgery,
Gastrointestinal Hospital, Sun Yat-sen Universtiy, Guangzhou 510655, China.
Received: 24 March 2015 Accepted: 23 October 2015
References
1. Geserick P, Kaiser F, Klemm U, Kaufmann SH, Zerrahn J. Modulation of T cell
development and activation by novel members of the Schlafen (slfn) gene
family harbouring an RNA helicase-like motif. Int Immunol. 2004;16:1535–48.
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al.
The Cancer Cell Line Encyclopedia enables predictive modelling of
anticancer drug sensitivity. Nature. 2012;483:603–7.
3. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al.
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to
DNA-damaging agents. Proc Natl Acad Sci U S A. 2012;109:15030–5.
4. Brady G, Boggan L, Bowie A, O’Neill LA. Schlafen-1 causes a cell cycle arrest
by inhibiting induction of cyclin D1. J Biol Chem. 2005;280:30723–34.
5. Sohn WJ, Kim D, Lee KW, Kim MS, Kwon S, Lee Y, et al. Novel transcriptional
regulation of the schlafen-2 gene in macrophages in response to TLR-triggered
stimulation. Mol Immunol. 2007;44:3273–82.
6. Neumann B, Zhao L, Murphy K, Gonda TJ. Subcellular localization of the
Schlafen protein family. Biochem Biophys Res Commun. 2008;370:62–6.
7. Bustos O, Naik S, Ayers G, Casola C, Perez-Lamigueiro MA, Chippindale PT,
et al. Evolution of the Schlafen genes, a gene family associated with
embryonic lethality, meiotic drive, immune processes and orthopoxvirus
virulence. Gene. 2009;447:1–11.
8. Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N,
et al. Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in
regulation of anchorage-independent growth and invasion of malignant
melanoma cells. J Biol Chem. 2010;285:40333–41.
9. Patel VB, Yu Y, Das JK, Patel BB, Majumdar AP. Schlafen-3: a novel regulator
of intestinal differentiation. Biochem Biophys Res Commun. 2009;388:752–6.
10. Yuan L, Yu Y, Sanders MA, Majumdar AP, Basson MD. Schlafen 3 induction
by cyclic strain regulates intestinal epithelial differentiation. Am J Physiol
Gastrointest Liver Physiol. 2010;298:G994-994G1003.
11. Walsh MF, Hermann R, Sun K, Basson MD. Schlafen 3 changes during rat
intestinal maturation. Am J Surg. 2012;204:598–601.
12. Patel BB, Yu Y, Du J, Rishi AK, Sarkar FH, Tarca AL, et al. Schlafen 3, a novel
gene, regulates colonic mucosal growth during aging. Am J Physiol
Gastrointest Liver Physiol. 2009;296:G955–962.
13. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ.
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep
(Oxf). 2013;1:166–83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Deng et al. BMC Cancer  (2015) 15:833 Page 7 of 7
